Satish Chandran
Chief Executive Officer
Infectious Diseases
Somahlution
India
Biography
Dr. Chandran co-founded Somahlution with Chairman Dr. Dhaduk, and has served as the Company’s Chief Executive and a member of the Board of Directors since inception in 2010. He is a distinguished biotechnology veteran with nearly 25 years of leadership positions. Until 2012, Dr. Chandran was the Director of the Center of Excellence for Biopharmaceutical Research & Development and Professor of Pharmaceutics at North Dakota State University. Prior to that, he was the Chief Technology Officer at the BioTx Division of Pfizer, in Cambridge. Previous to Pfizer, he was a Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, and was the Chief Operating Officer and Chief Scientific Officer at Nucleonics, the first RNAi-based company, in Horsham PA, a company that he cofounded while on the faculty at Thomas Jefferson University’s Biochemistry Department. Prior to founding Nucleonics, Dr. Chandran led the DNA Vaccine Division of Wyeth-Lederle Vaccines following its 1998 acquisition of Apollon, Inc., a biotech company in Malvern, PA, focused on advancing DNA vaccine-based product candidates for infectious diseases and cancer. Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.
Research Interest
Prior to founding Nucleonics, Dr. Chandran led the DNA Vaccine Division of Wyeth-Lederle Vaccines following its 1998 acquisition of Apollon, Inc., a biotech company in Malvern, PA, focused on advancing DNA vaccine-based product candidates for infectious diseases and cancer. Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.
